HUE053236T2 - Adenovírus és ellenõrzõpont-gátlók kombinálása rák kezelésére - Google Patents

Adenovírus és ellenõrzõpont-gátlók kombinálása rák kezelésére

Info

Publication number
HUE053236T2
HUE053236T2 HUE16188301A HUE16188301A HUE053236T2 HU E053236 T2 HUE053236 T2 HU E053236T2 HU E16188301 A HUE16188301 A HU E16188301A HU E16188301 A HUE16188301 A HU E16188301A HU E053236 T2 HUE053236 T2 HU E053236T2
Authority
HU
Hungary
Prior art keywords
treating cancer
checkpoint inhibitors
adenovirus
combining
combining adenovirus
Prior art date
Application number
HUE16188301A
Other languages
English (en)
Inventor
Tuuli Ranki
Sari Pesonen
Magnus Jäderberg
Elina Haavisto
Lukasz Kuryk
Antti Vuolanto
Original Assignee
Targovax Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targovax Oy filed Critical Targovax Oy
Publication of HUE053236T2 publication Critical patent/HUE053236T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HUE16188301A 2016-09-12 2016-09-12 Adenovírus és ellenõrzõpont-gátlók kombinálása rák kezelésére HUE053236T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16188301.2A EP3293201B1 (en) 2016-09-12 2016-09-12 Combining adenovirus and checkpoint inhibitors for treating cancer

Publications (1)

Publication Number Publication Date
HUE053236T2 true HUE053236T2 (hu) 2021-06-28

Family

ID=56926041

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16188301A HUE053236T2 (hu) 2016-09-12 2016-09-12 Adenovírus és ellenõrzõpont-gátlók kombinálása rák kezelésére

Country Status (14)

Country Link
US (2) US10940203B2 (hu)
EP (2) EP3293201B1 (hu)
JP (2) JP7146739B2 (hu)
CN (1) CN109715664A (hu)
AU (1) AU2017324482A1 (hu)
DK (1) DK3293201T3 (hu)
ES (1) ES2845690T3 (hu)
HR (1) HRP20210133T1 (hu)
HU (1) HUE053236T2 (hu)
LT (1) LT3293201T (hu)
PL (1) PL3293201T3 (hu)
PT (1) PT3293201T (hu)
SI (1) SI3293201T1 (hu)
WO (1) WO2018046803A1 (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350275B2 (en) * 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
US11090344B2 (en) 2016-05-27 2021-08-17 Dnatrix, Inc. Adenovirus and immunomodulator combination therapy
US20190275092A1 (en) 2016-11-01 2019-09-12 Dnatrix, Inc. Combination therapy for treatment of brain cancers
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
CN114426945A (zh) * 2021-11-10 2022-05-03 西安交通大学医学院第一附属医院 胶质瘤类器官原代促活液、培养液及制备、培养方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2304281B1 (es) * 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
EP2379586B1 (en) 2008-12-22 2016-11-02 Targovax Oy Oncolytic adenoviral vectors and methods and uses related thereto
FI20090030A0 (fi) * 2009-02-02 2009-02-02 Akseli Eetu Hemminki Onkolyyttiset virukset
CN104704002B (zh) 2012-08-30 2022-05-10 安姆根有限公司 使用单纯疱疹病毒和免疫检查点抑制剂治疗黑色素瘤的方法
US20150250837A1 (en) 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
US10350275B2 (en) 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
EP3653714A1 (en) * 2013-11-22 2020-05-20 DNAtrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)

Also Published As

Publication number Publication date
EP3293201A1 (en) 2018-03-14
JP2022183170A (ja) 2022-12-08
WO2018046803A1 (en) 2018-03-15
EP3293201B1 (en) 2020-11-04
CN109715664A (zh) 2019-05-03
LT3293201T (lt) 2021-03-25
US10940203B2 (en) 2021-03-09
HRP20210133T1 (hr) 2021-03-19
JP2019532047A (ja) 2019-11-07
SI3293201T1 (sl) 2021-03-31
PL3293201T3 (pl) 2021-06-14
AU2017324482A1 (en) 2019-04-11
US20190201525A1 (en) 2019-07-04
ES2845690T3 (es) 2021-07-27
PT3293201T (pt) 2020-12-07
EP3783032A1 (en) 2021-02-24
US11690913B2 (en) 2023-07-04
DK3293201T3 (da) 2020-12-07
JP7146739B2 (ja) 2022-10-04
US20210121564A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
IL272470A (en) Methods and materials for the evaluation and treatment of cancer
IL267247B (en) Compositions and methods for treating cancer
HK1245677A1 (zh) 用於治療炎症和癌症的雜環itk抑制劑
HK1251862A1 (zh) 治療癌症的方法和組合物
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
HK1249469A1 (zh) 用RORγ抑制劑治療癌症的方法
HK1248602A1 (zh) 治療癌症的組合物及方法
PT3293201T (pt) Combinação de adenovírus e inibidores de ponto de verificação para tratamento do cancro
IL271019A (en) Tinostemustine for the treatment of ovarian cysts
EP3271483A4 (en) Methods and materials for assessing and treating cancer
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
IL255638A (en) Compositions and methods for treating cancer
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
PL3290051T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
EP3273970A4 (en) Methods and materials for treating cancer
EP3672619A4 (en) MATERIALS AND METHODS FOR EVALUATING CANCER RISK AND TREATING CANCER
ZA201802268B (en) Methods and compositions for preventing or treating cancer
IL274714A (en) Methods and materials for cancer assessment and treatment
HK1250958A1 (zh) 用於治療癌症的組合物和方法
IL255541A (en) Cabazitaxel and its use for treating cancer
RS62660B1 (sr) Rad1901 za upotrebu u lečenju karcinoma jajnika
PL3402889T3 (pl) Skojarzenie adenowirusa i środków chemioterapeutycznych do leczenia raka
GB201720089D0 (en) Means and methods for treating cancer
GB201609402D0 (en) Materials and methods for treating cancer